Related Experiment Videos
Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy
Gregory A Wiseman1, Bryan R Leigh, William L Dunn
1Mayo Clinic, Rochester, MN 55905, USA. gwiseman@mayo.edu
Cancer Biotherapy & Radiopharmaceuticals
|June 14, 2003
Summary
Zevalin radioimmunotherapy significantly improved response rates in non-Hodgkin's lymphoma patients compared to rituximab alone. Dosimetry confirmed radiation doses to organs and marrow were within safe limits.
Area of Science:
- Oncology
- Nuclear Medicine
- Immunotherapy
Background:
- Non-Hodgkin's lymphoma (NHL) requires effective treatments for relapsed or refractory cases.
- Radioimmunotherapy offers a targeted approach for certain hematologic malignancies.
Purpose of the Study:
- To evaluate the efficacy and safety of Zevalin (ibritumomab tiuxetan) radioimmunotherapy for NHL.
- To assess radiation dosimetry for Zevalin treatment.
Main Methods:
- A Phase III, randomized study compared Zevalin plus rituximab to rituximab alone in 143 NHL patients.
- Patients received (111)In-labeled Zevalin for imaging followed by (90)Y-labeled Zevalin for therapy.
- Radiation dosimetry was performed on a subset of patients using (111)In imaging and MIRDOSE3.1 software.
Main Results:
- The Zevalin regimen achieved a significantly higher overall response rate (80%) versus rituximab alone (56%, p=0.02).
- Radiation absorbed dose estimates were highest for spleen, testes, and liver.
- Doses to other organs and red marrow were within a safe range.
Conclusions:
- Zevalin radioimmunotherapy is an effective treatment option for relapsed or refractory, low-grade, follicular, or transformed NHL.
- The administered radiation doses associated with Zevalin therapy are considered safe for normal tissues and marrow.